NFKB1 and mantle cell lymphoma: Rahal et al. demonstrated that constitutive NF-κB activity in a subgroup of MCL patients caused resistance to the BTK inhibitor ibrutinib, highlighting the importance of NF-κB in MCL therapy resistance and relapse [19].